Adlai Nortye Biopharma Co. Ltd. and Adlai Nortye Pte Ltd. have divulged cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammatory disorders and autoimmune diseases.
Scinnohub Pharmaceutical Co. Ltd. has divulged cyclin-dependent kinase (CDK) inhibitors, particularly CDK9 inhibitors, reported to be useful for the treatment of cancer.
Scientists at Foshan Ionova Biotherapeutics Co. Ltd., Guangdong Touchstone Translational Research Institute Co. Ltd. and Shenzhen Ionova Life Science Co. Ltd. have described tricyclic compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK1/cyclin B and/or CDK2/cyclin E1 and/or CDK4/cyclin D3 and/or CDK6/cyclin D3 inhibitors, reported to be useful for the treatment of cancer.
China Pharmaceutical University scientists have published details on the discovery and preclinical evaluation of a glutathione peroxidase 4 (GPX4) and cyclin-dependent kinase (CDK) dual inhibitor being developed for the treatment of cancer.
The H. Lee Moffitt Cancer Center and Research Institute has described cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer, inflammation and myotonic dystrophy type 1 disease.
Iambic Therapeutics Inc. has disclosed quinazoline compounds acting as cyclin-dependent kinase (CDK) inhibitors, particularly CDK2 and/or CDK4 and/or CDK6 inhibitors reported to be useful for the treatment of ovarian and breast cancer.
Research at Prelude Therapeutics Inc. has led to the identification of thaizole-pyrimdiine cyclin-dependent kinase (CDK) inhibitors reported to be useful for the treatment of cancer.
